[lu-177]-pnt2002,abiraterone,enzalutamide
pfizer,astellas,point biopharma,janssen
['splash', 'crpc', '$pnt', 'pointbiopharma']
point provides updated efficacy &amp; safety data from the lead-in cohort of the phase 3 splash trial in mcrpc at esmo 2022. poster on the single-arm 27-patient safety &amp; dosimetry lead-in provides key updates including a median rpfs time of 11.5 months... $pnt 
We are a next generation radiopharmaceutical company, taking cancer head on.